When was Aspen Neuroscience founded?

Aspen Neuroscience was founded in 2018 and raised its 1st funding round 1 year after it was founded.

Where is Aspen Neuroscience located?

Aspen Neuroscience is headquartered in San Diego, United States.

Who is the current CEO of Aspen Neuroscience?

Kim Kamdar and Howard Federoff s of Aspen Neuroscience. Kim Kamdar has also founded 1 company.

How many employees does Aspen Neuroscience have?

As of Mar 31, 2026, the latest employee count at Aspen Neuroscience is 124.

Is Aspen Neuroscience a funded company?

Aspen Neuroscience is a funded company, having raised a total of $339M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Dec 12, 2019.

When was the latest funding round of Aspen Neuroscience?

Aspen Neuroscience's latest funding was a $***** Series C round on Nov 20, 2025, with participation from 13 investors.

Where does Aspen Neuroscience rank among its competitors?

Aspen Neuroscience ranks 25th amongst 640 active competitors, of which 243 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Aspen Neuroscience, which secured $115M in Nov, 2025.

Who are the top competitors of Aspen Neuroscience?

Aspen Neuroscience's top competitors include Sana Biotechnology, Spark Therapeutics and Fulcrum Therapeutics. Among them, Aspen Neuroscience secured the most recent funding round in November, 2025.

Aspen Neuroscience - 2026 Company Profile, Team, Funding & Competitors

Company Details

Provider of genomic-based personalized pluripotent stem cell therapy. It offers regenerative cell treatment like dopaminergic neurons for Parkinson's disease and other neurological disorders. It maintains the genetic-based quality control to avoid the mutation of cells used for therapy.

Website: aspenneuroscience.com
Social

Key Metrics

Founded Year

2018

Location

San Diego, United States

Stage

Series C

Total Funding

$339M in 5 rounds

Latest Funding Round

Series C, Nov 20, 2025, $*****

Investors

Orbimed & 23 more

Ranked

25^th among 640 active competitors

Employee Count

124 as on Mar 31, 2026

Similar Companies

Sana Biotechnology & 786 more

View Aspen Neuroscience's full profile

Aspen Neuroscience has raised a total funding of $339M over 5 rounds. Its first funding round was on Dec 12, 2019. Its latest funding round was a Series C round on Nov 20, 2025 for $*****. 13 investors participated in its latest round. Aspen Neuroscience has 23 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Aspen Neuroscience:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 20, 2025	3454533	Series C	5955174	7201587	3730177	6340507
Dec 21, 2022	4369642	Conventional Debt	9237675	5188890	2656936	SVB
May 09, 2022	1944722	Series B	7245216	6198178	Google Ventures & 2 more	Newton Investment Management & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of Aspen Neuroscience's funding rounds and investors

The founders of Aspen Neuroscience is Kim Kamdar.

Here are the details of Aspen Neuroscience's key team members:

Kim Kamdar: Co-Founder of Aspen Neuroscience and founder of 1 other company.
Howard Federoff: Co-Founder of Aspen Neuroscience and founder of 1 other company.

View details of Aspen Neuroscience's Founder profiles and Board Members

Aspen Neuroscience's employee count trend

Aspen Neuroscience has 124 employees as of Mar 26. Here is Aspen Neuroscience's employee count trend over the years:

Employee count trend for Aspen Neuroscience

Uncover Aspen Neuroscience's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Aspen Neuroscience include Sana Biotechnology, Spark Therapeutics and Fulcrum Therapeutics. Here is the list of Top 10 competitors of Aspen Neuroscience, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
2nd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Wellington & 6 others	74/100
3rd	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Google Ventures & 15 others	71/100
4th	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, BB Biotech & 13 others	70/100
5th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	70/100
6th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
7th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	Aisling Capital, RA Capital Management & 7 others	70/100
8th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	F-Prime Capital, Adage Capital Management ... & 9 others	69/100
9th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
10th	Krystal Biotech 2015, Pittsburgh (United States), Public	Developer of genetic medicines to treat rare diseases	$11.3M	Frazier Life Sciences, Danforth Advisors & 2 others	69/100
25th	Aspen Neuroscience 2018, San Diego (United States), Series C	Provider of genomic-based personalised pluripotent stem cell therapy	$339M	Domain Associates, Timefolio Capital & 22 others	65/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Aspen Neuroscience's competitors? Click here to see the top ones

Aspen Neuroscience has made no investments or acquisitions yet.

Media has covered Aspen Neuroscience for a total of 5 events in the last 1 year, 2 of them have been about company updates and 1 about people movement.